Clinical Trials on Impaired Cognition in Argentina

Total 16 results

FORUM Pharmaceuticals Inc
Syneos Health; NeuroCog Trials, Inc.

Completed

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Schizophrenia | Impaired Cognition

United States, Australia, Poland, Ukraine, Germany, Spain, Argentina, Serbia, Canada, Singapore, Russian Federation, Brazil, Mexico
FORUM Pharmaceuticals Inc
Syneos Health; NeuroCog Trials, Inc.

Completed

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Schizophrenia | Impaired Cognition

United States, Ukraine, United Kingdom, Poland, Romania, Russian Federation, Italy, Mexico, Colombia, Argentina, Australia, Brazil
FORUM Pharmaceuticals Inc
Syneos Health

Completed

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Schizophrenia | Impaired Cognition

United States, Ukraine, United Kingdom, Germany, Spain, Argentina, Canada, Singapore, Russian Federation, Italy, Mexico, Colombia, Australia, Belgium, Poland, Romania
Hospital Italiano de Buenos Aires

Completed

Post Operative Cognitive Dysfunction (POCD)

Postoperative Complications

Argentina
National Council of Scientific and Technical Research...

Completed

Naturalistic Study of Microdosing With Psilocybin (NATMICRO)

Sleep | Cognitive Change | Mood Change | Creativity

Argentina
Alba Maria Ropero
Centers for Disease Control and Prevention; Ministry of Public Health, Argentina

Completed

Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines

Vaccine Response Impaired

Argentina
University of Gran Rosario

Completed

Effects of Transcranial Direct Current Stimulation (tDCS) on Rotator Cuff Fatigue.

Asymptomatic Condition

Argentina
Johnson & Johnson Pharmaceutical Research & Development...

Completed

An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine

Mild Cognitive Impairment

United States, United Kingdom, Belgium, Germany, Spain, Argentina, Israel, Poland, Australia, Canada, Netherlands, Finland, Austria, Sweden, France, Czech Republic
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia

COVID-19 Pneumonia, Impaired Respiratory Function

Germany, India, Spain, Russian Federation, Mexico, Netherlands, Peru, Brazil, Hungary, Argentina, Denmark, South Africa
Hospital Italiano de Buenos Aires

Completed

Cognitive Performance After a Night Shift in Internal Medicine Residents

Burnout, Professional | Cognition Disorders | Sleep Deprivation

Argentina
Universitat Jaume I

Unknown

Efficacy and Effectiveness of a Self-applied Online Program to Promote Resilience and Coping Skills in College Students

CORE Condition | Healthy Lifestyle Psychoeducational Program | Waiting List Control

Argentina, Mexico, Spain
Solvay Pharmaceuticals
Quintiles, Inc.

Terminated

Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function

Congestive Heart Failure

United States, Argentina, Belgium, Czech Republic, Former Serbia and Montenegro, Germany, Poland, Russian Federation, South Africa, Spain
AstraZeneca

Recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function (BalanceD-HF)

Heart Failure and Impaired Kidney Function

Spain, France, Germany, Italy, United States, Argentina, Czechia, Vietnam, Peru, China, Philippines, Austria, Canada, Japan, Malaysia, Poland, Taiwan, Thailand, Brazil, Finland, Greece, Israel, Mexico, United Kingdom, Turkey, Colombia, Slov... and more
Hoffmann-La Roche

Recruiting

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.

Huntington Disease

United States, Australia, Argentina, Canada, Germany, Italy, Spain, France, United Kingdom, Portugal, New Zealand, Austria, Poland, Switzerland, Denmark
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

Huntingtons Disease

United States, United Kingdom, Australia, Canada, Japan, Poland, Netherlands, Germany, Russian Federation, France, Spain, Argentina, New Zealand, Austria, Denmark, Italy, Switzerland, Chile
CHDI Foundation, Inc.

Recruiting

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Huntington's Disease

United States, Canada, Belgium, Spain, Australia, Germany, France, Netherlands, United Kingdom, New Zealand, Argentina, Austria, Chile, Colombia, Denmark, Ireland, Italy, Poland, Portugal, Switzerland

Clinical Trials on Impaired Cognition in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations